Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
McKesson
Moodys
Dow
AstraZeneca

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Siltuximab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Siltuximab: Patents, clinical trial progress, indications

Siltuximab is an investigational drug.

There have been 18 clinical trials for Siltuximab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Schizophrenia. The leading clinical trial sponsors are Janssen Research & Development, LLC, Centocor, Inc., and Brian Miller.

There are eleven US patents protecting this investigational drug and four hundred and twenty-six international patents.

Recent Clinical Trials for Siltuximab
TitleSponsorPhase
Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseUniversity of PennsylvaniaPhase 2
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisJanssen Scientific Affairs, LLCPhase 2
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisMemorial Sloan Kettering Cancer CenterPhase 2

See all Siltuximab clinical trials

Clinical Trial Summary for Siltuximab

Top disease conditions for Siltuximab
Top clinical trial sponsors for Siltuximab

See all Siltuximab clinical trials

US Patents for Siltuximab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Siltuximab   See Pricing Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   See Pricing
Siltuximab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Siltuximab   See Pricing Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)   See Pricing
Siltuximab   See Pricing Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)   See Pricing
Siltuximab   See Pricing P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Siltuximab

Drugname Country Document Number Estimated Expiration Related US Patent
Siltuximab Canada 2900764 2033-02-08   See Pricing
Siltuximab European Patent Office 2954056 2033-02-08   See Pricing
Siltuximab Hong Kong 1218930 2033-02-08   See Pricing
Siltuximab Japan 2016509014 2033-02-08   See Pricing
Siltuximab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKinsey
Dow
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.